208 related articles for article (PubMed ID: 3343728)
21. [Neoadjuvant chemotherapy with MVC (methotrexate, vinblastine, cisplatin)in the treatment of infiltrating transitional carcinoma of the bladder].
Campo B; Torelli T; Leidi GL; Corrada P; Bacchioni AM; Ordesi G; Zanitzer L
Arch Ital Urol Nefrol Androl; 1990 Jun; 62(2):237-42. PubMed ID: 2142807
[TBL] [Abstract][Full Text] [Related]
22. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
[TBL] [Abstract][Full Text] [Related]
23. [Neoadjuvant chemotherapy (M-VAC) in invasive cancer of the bladder. Our experience].
González Enguita C; Caro Cebrián C; Roncalés Badal A; Gil Sanz MJ; Martínez Bengoechea J; Rioja Sanz LA
Arch Esp Urol; 1990; 43 Suppl 2():197-204. PubMed ID: 2096779
[TBL] [Abstract][Full Text] [Related]
24. The efficacy of neoadjuvant chemotherapy in invasive bladder cancer.
Cam K; Yildirim A; Ozveri H; Turkeri L; Akdas A
Int Urol Nephrol; 2002; 33(1):49-52. PubMed ID: 12090338
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy of advanced transitional-cell carcinoma of the bladder.
Miller RS; Torti FM
Cancer Chemother Pharmacol; 1992; 30 Suppl():S99-110. PubMed ID: 1394829
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant treatment of stages T2 to T4 bladder cancer with cis-platinum, cyclophosphamide and doxorubicin.
McCullough DL; Cooper RM; Yeaman LD; Loomer L; Woodruff RD; Boyce WH; Harrison LH; Assimos DG; Lynch DF
J Urol; 1989 Apr; 141(4):849-52. PubMed ID: 2926878
[TBL] [Abstract][Full Text] [Related]
27. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy for locally advanced transitional cell carcinoma of the bladder: do local findings suggest a potential for salvage of the bladder?
Zincke H; Sen SE; Hahn RG; Keating JP
Mayo Clin Proc; 1988 Jan; 63(1):16-22. PubMed ID: 3336237
[TBL] [Abstract][Full Text] [Related]
29. Study of the prediction system for clinical response to M-VAC neoadjuvant chemotherapy for bladder cancer.
Takata R; Obara W; Fujioka T
Aktuelle Urol; 2010 Jan; 41 Suppl 1():S41-5. PubMed ID: 20094952
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy for bladder cancer: the MSKCC experience.
Fair WR; Scher H; Herr H; Morse M; Sogani P; Bosi G; Dershaw D; Reuter V; Curley T
Semin Urol; 1990 Aug; 8(3):190-6. PubMed ID: 2399387
[No Abstract] [Full Text] [Related]
31. Can patient selection for bladder preservation be based on response to chemotherapy?
Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
[TBL] [Abstract][Full Text] [Related]
32. [Current status of adjuvant chemotherapy of invasive bladder cancer].
Ozono S; Sasaki K; Watanabe S; Maruyama Y; Ohara S; Babaya K; Yamada K; Hirao Y; Okajima E
Hinyokika Kiyo; 1991 Dec; 37(12):1589-95. PubMed ID: 1785379
[TBL] [Abstract][Full Text] [Related]
33. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
Hata M; Miyanaga N; Tokuuye K; Saida Y; Ohara K; Sugahara S; Kagei K; Igaki H; Hashimoto T; Hattori K; Shimazui T; Akaza H; Akine Y
Int J Radiat Oncol Biol Phys; 2006 Apr; 64(5):1371-9. PubMed ID: 16580495
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant systemic chemotherapy after complete transurethral resection of superficially invasive bladder carcinoma (T1 G3-4 and T2 G2-4).
Rübben H; Weissbach L; Knebel L; Deutz FJ; Giani G; Graf-Dobberstein C; Gebhard R
Urol Int; 1990; 45(2):78-83. PubMed ID: 2184564
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer--Genitourinary Group.
Splinter TA; Scher HI; Denis L; Bukowski R; Simon S; Klimberg I; Soloway M; Vogelzang NJ; van Tinteren H; Herr H
J Urol; 1992 Mar; 147(3):606-8. PubMed ID: 1538438
[TBL] [Abstract][Full Text] [Related]
36. [Methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial cancer--analysis of efficacy and toxicity].
Igawa M; Kadena H; Ohkuchi T; Ueda M; Usui T
Nihon Hinyokika Gakkai Zasshi; 1991 Oct; 82(10):1627-36. PubMed ID: 1770701
[TBL] [Abstract][Full Text] [Related]
37. Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy.
Prout GR; Shipley WU; Kaufman DS; Heney NM; Griffin PP; Althausen AF; Bassil B; Nocks BN; Parkhurst EC; Young HH
J Urol; 1990 Nov; 144(5):1128-34; discussion 1134-6. PubMed ID: 2122007
[TBL] [Abstract][Full Text] [Related]
38. Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?
Siref LE; Zincke H
Urology; 1988 Apr; 31(4):309-11. PubMed ID: 3354121
[TBL] [Abstract][Full Text] [Related]
39. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
Lehmann J; Retz M; Hack M; Siemer S; Stöckle M
Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
[TBL] [Abstract][Full Text] [Related]
40. [Polychemotherapy in advanced bladder cancer. Practicality and clinical results].
Klän R; Knispel H; Huland H
Urologe A; 1992 Jul; 31(4):247-50. PubMed ID: 1514213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
